- Home
- GNS vs TENX Comparison
GNS vs TENX Comparison
Compare GNS & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNS
- TENX
- Stock Information
- Founded
- GNS 2002
- TENX 1967
- Country
- GNS Singapore
- TENX United States
- Employees
- GNS N/A
- TENX N/A
- Industry
- GNS Other Consumer Services
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- GNS Real Estate
- TENX Health Care
- Exchange
- GNS Nasdaq
- TENX Nasdaq
- Market Cap
- GNS 23.4M
- TENX 21.7M
- IPO Year
- GNS 2022
- TENX N/A
- Fundamental
- Price
- GNS $0.25
- TENX $6.30
- Analyst Decision
- GNS
- TENX Strong Buy
- Analyst Count
- GNS 0
- TENX 3
- Target Price
- GNS N/A
- TENX $16.00
- AVG Volume (30 Days)
- GNS 1.6M
- TENX 20.7K
- Earning Date
- GNS 05-14-2025
- TENX 05-13-2025
- Dividend Yield
- GNS N/A
- TENX N/A
- EPS Growth
- GNS N/A
- TENX N/A
- EPS
- GNS N/A
- TENX N/A
- Revenue
- GNS $16,147,348.00
- TENX N/A
- Revenue This Year
- GNS N/A
- TENX N/A
- Revenue Next Year
- GNS $47.43
- TENX N/A
- P/E Ratio
- GNS N/A
- TENX N/A
- Revenue Growth
- GNS N/A
- TENX N/A
- 52 Week Low
- GNS $0.21
- TENX $2.77
- 52 Week High
- GNS $5.69
- TENX $7.89
- Technical
- Relative Strength Index (RSI)
- GNS 38.79
- TENX 49.26
- Support Level
- GNS $0.21
- TENX $6.00
- Resistance Level
- GNS $0.33
- TENX $6.76
- Average True Range (ATR)
- GNS 0.04
- TENX 0.40
- MACD
- GNS -0.00
- TENX 0.02
- Stochastic Oscillator
- GNS 30.36
- TENX 39.47
About GNS Genius Group Limited
Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. The company's business consists of two reportable business segments: Education - entrepreneur education, management consultancy, and business development tools; and Campus - resorts, retreats, and co-working cafes for entrepreneurs. It derives the majority of its revenue from the Education segment.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.